{
    "pubmed_id": 34759001,
    "study_identifier": "PMID34759001_study",
    "study_name": "Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer",
    "publication_title": "Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer",
    "study_objective": "Long-term studies of immunogenicity of SARS-CoV-2 vaccines in patients with cancer are needed to inform evidence-based guidelines for booster vaccinations and to tailor sequence and timing of vaccinations to elicit improved humoral responses.",
    "study_description": "Longitudinal studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced immune responses in patients with cancer are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD) and anti-nucleocapsid immunoglobulin] at three time points. Antibody level trajectories and frequency of breakthrough infections were evaluated by tumor type and timing of treatment relative to vaccination. IgG-(S-RBD) at peak response (median = 42 days after dose 2) was higher (P = 0.002) and remained higher after 4 to 6 months (P = 0.003) in patients receiving mRNA-1273 compared with BNT162b2. Patients with solid tumors attained higher peak levels (P = 0.001) and sustained levels after 4 to 6 months (P < 0.001) compared with those with hematologic malignancies. B-cell targeted treatment reduced peak (P = 0.001) and sustained antibody responses (P = 0.003). Solid tumor patients receiving immune checkpoint inhibitors before vaccination had lower sustained antibody levels than those who received treatment after vaccination (P = 0.043). Two (0.69%) vaccinated and one (1.9%) unvaccinated patient had severe COVID-19 illness during follow-up. Our study shows variation in sustained antibody responses across cancer populations receiving various therapeutic modalities, with important implications for vaccine booster timing and patient selection. SIGNIFICANCE: Long-term studies of immunogenicity of SARS-CoV-2 vaccines in patients with cancer are needed to inform evidence-based guidelines for booster vaccinations and to tailor sequence and timing of vaccinations to elicit improved humoral responses.",
    "primary_institution_name": "Cedars-Sinai",
    "study_personnel": [
        {
            "personnel_id": "PMID34759001_personnel-01",
            "honorific": "",
            "last_name": "Cheng",
            "first_name": "Susan",
            "suffixes": "",
            "organization": "Cedars-Sinai",
            "orchid_id": "",
            "email": "Susan.Cheng@cshs.org",
            "seronet_title_in_study": "SeroNet Principal Investigator",
            "role_in_study": "Investigator",
            "site_name": "Cedars-Sinai"
        },
        {
            "personnel_id": "PMID34759001_personnel-02",
            "honorific": "",
            "last_name": "Figueiredo",
            "first_name": "Jane",
            "suffixes": "",
            "organization": "Cedars-Sinai",
            "orchid_id": "",
            "email": "Jane.Figueiredo@cshs.org",
            "seronet_title_in_study": "Corresponding Author",
            "role_in_study": "Corresponding Author",
            "site_name": "Cedars-Sinai"
        }
    ],
    "study_file": [
        {
            "study_file_name": "PMID34759001_Supplementary Appendix.docx",
            "study_file_description": "Supplementary data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID34759001_longitudinal_cancer_re_paper_data_040622.csv",
            "study_file_description": "Demographics and SARS-CoV-2 IgG assay results",
            "study_file_type": "Assessment results"
        },
        {
            "study_file_name": "PMID34759001_v1.2.5.xlsm",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors",
            "study_file_type": "Study Summary Description"
        },
        {
            "study_file_name": "PMID34759001_JSON.json",
            "study_file_description": "JSON format of completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [],
    "research_focus": "Vaccine Response",
    "study_type": "Clinical research",
    "keyword": [
        "2019-nCoV Vaccine mRNA-1273",
        "Adult",
        "Aged",
        "Antibodies",
        "Viral",
        "BNT162 Vaccine",
        "COVID-19",
        "Female",
        "Humans",
        "Immunity",
        "Humoral",
        "Immunization Programs",
        "Immunoglobulin G",
        "Longitudinal Studies",
        "Male",
        "Middle Aged",
        "Neoplasms",
        "Prospective Studies",
        "SARS-CoV-2",
        "Surveys and Questionnaires",
        "Time Factors",
        "Chemiluminescent Assay"
    ],
    "clinical_study_design": "Longitudinal Study",
    "in_silico_model_type": "",
    "protocol": {
        "protocol_id": "PMID34759001_protocol-01",
        "protocol_file_name": "PMID34759001_protocol-01.txt",
        "protocol_name": "PMID34759001_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19",
        "Cancer"
    ],
    "sars_cov_2_vaccine_type": [
        "Pfizer-BioNTech SARS-CoV-2 vaccine",
        "Moderna SARS-CoV-2 vaccine"
    ],
    "clinical_outcome_measure": "",
    "enrollment_start_date": "",
    "enrollment_end_date": "",
    "number_of_study_subjects": 1612,
    "age_unit": "Years",
    "minimum_age": 18,
    "maximum_age": 91,
    "study_human_cohort": [
        {
            "arm_id": "PMID34759001_human_subject-01",
            "arm_name": "Unvaccinated cancer patients",
            "study_population_description": "Unvaccinated cancer patients (n=54)",
            "arm_type": "Observational",
            "ethnicity": [
                "Not Hispanic or Latino"
            ],
            "race": [
                "Other"
            ],
            "race_specify": [
                "Asian",
                "Other",
                "Black or African American"
            ],
            "description": "",
            "sex_at_birth": [
                "Male",
                "female"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: California"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [
                "Self Reported"
            ],
            "assessment_demographic_data_types_collected": [
                "demographics, lifestyle/behaviors"
            ],
            "sars_cov_2_history": [
                "Uninfected",
                "Infected"
            ],
            "sars_cov_2_vaccine_type": [],
            "covid_19_disease_severity": [
                "Unknown"
            ],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34759001_human_subject-02",
            "arm_name": "Vaccinated cancer patients",
            "study_population_description": "Vaccinated cancer patients (n=291) with two doses mRNA vaccine",
            "arm_type": "Observational",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Hispanic or Latino"
            ],
            "race": [
                "Other"
            ],
            "race_specify": [
                "Asian",
                "Other",
                "Black or African American"
            ],
            "description": "",
            "sex_at_birth": [
                "Male",
                "female"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: California"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [
                "Self Reported"
            ],
            "assessment_demographic_data_types_collected": [
                "demographics, lifestyle/behaviors"
            ],
            "sars_cov_2_history": [
                "Uninfected",
                "Infected"
            ],
            "sars_cov_2_vaccine_type": [
                "Moderna COVID-19 vaccine ; VO:0005157",
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987"
            ],
            "covid_19_disease_severity": [
                "Unknown"
            ],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34759001_human_subject-03",
            "arm_name": "Health Care Workers without a history of cancer",
            "study_population_description": "Health care workers (HCW) at Cedar-Sinai Health System over age 18 without a history of cancer. (n=1246)",
            "arm_type": "Observational",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Hispanic or Latino"
            ],
            "race": [
                "Other"
            ],
            "race_specify": [
                "Asian",
                "Other",
                "Black or African American",
                "unknown"
            ],
            "description": "",
            "sex_at_birth": [
                "Male",
                "female"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: California"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [
                "Self Reported"
            ],
            "assessment_demographic_data_types_collected": [
                "demographics, lifestyle/behaviors"
            ],
            "sars_cov_2_history": [
                "Uninfected",
                "Infected"
            ],
            "sars_cov_2_vaccine_type": [],
            "covid_19_disease_severity": [
                "Unknown"
            ],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [],
    "planned_visit": [
        {
            "visit_id": "PMID34759001_pv-01",
            "visit_name": "Enrollment (prior to dose 1 vaccination for vaccinated patients, n = 112)",
            "visit_order_number": 1,
            "visit_min_start_day": 0,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34759001_pv-02",
            "visit_name": "Peak response (2\u201312 weeks post two-dose for vaccinated patients, n = 147)",
            "visit_order_number": 2,
            "visit_min_start_day": 14,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34759001_pv-03",
            "visit_name": "Sustained response (16\u201328 weeks after two-dose for vaccinated patients, n = 124)",
            "visit_order_number": 3,
            "visit_min_start_day": 112,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34759001_assessment_recorded_pv",
            "visit_name": "Visit where an assessment is recorded",
            "visit_order_number": 4,
            "visit_min_start_day": 0,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID34759001_human_subject-01, PMID34759001_human_subject-02, PMID34759001_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID34759001_pv-01, PMID34759001_pv-02, PMID34759001_pv-03"
            ],
            "assay_type": "Chemiluminescent Assay",
            "experiment_name": "SARS-CoV-2 IgG II assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Blood"
            ],
            "biospecimen_collection_point": [
                "Pre-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)",
                "S1",
                "Nucleocapsid"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34759001_human_subject-01, PMID34759001_human_subject-02, PMID34759001_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID34759001_pv-01, PMID34759001_pv-02, PMID34759001_pv-03"
            ],
            "assay_type": "Chemiluminescent Assay",
            "experiment_name": "SARS-CoV-2 IgG II assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Blood"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)",
                "S1",
                "Nucleocapsid"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34759001_human_subject-01, PMID34759001_human_subject-02, PMID34759001_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID34759001_pv-01, PMID34759001_pv-02, PMID34759001_pv-03"
            ],
            "assay_type": "Chemiluminescent Assay",
            "experiment_name": "SARS-CoV-2 IgG assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Blood"
            ],
            "biospecimen_collection_point": [
                "Pre-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)",
                "S1",
                "Nucleocapsid"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34759001_human_subject-01, PMID34759001_human_subject-02, PMID34759001_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID34759001_pv-01, PMID34759001_pv-02, PMID34759001_pv-03"
            ],
            "assay_type": "Chemiluminescent Assay",
            "experiment_name": "SARS-CoV-2 IgG assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Blood"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)",
                "S1",
                "Nucleocapsid"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        }
    ],
    "geriatric_subjects": "No",
    "pediatric_subjects": "Not Specified",
    "pregnant_subjects": "Not Specified",
    "sars_cov_2_antibodies_measured": "Not Specified",
    "survey_instrument_shared": "Not Specified",
    "who_disease_severity_scale_used": "Not Specified",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID34759001_inexcl-01",
            "inclusion_criterion": "Geriatric subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34759001_inexcl-02",
            "inclusion_criterion": "Subjects with cancer",
            "inclusion_criterion_category": "inclusion"
        }
    ],
    "suggestions": [
        "0.001",
        "0.002",
        "0.003",
        "0.043",
        "0.69",
        "1.9",
        "2019-ncov vaccine mrna-1273",
        "291",
        "366",
        "across",
        "acute",
        "adult",
        "aged",
        "anti-nucleocapsid",
        "anti-spike",
        "antibodies",
        "antibody",
        "attained",
        "b-cell",
        "bnt162 vaccine",
        "bnt162b2",
        "booster",
        "breakthrough",
        "cancer",
        "care",
        "cedars-sinai",
        "checkpoint",
        "chemiluminescent assay",
        "clinical",
        "cohort",
        "compared",
        "coronavirus",
        "covid-19",
        "days",
        "dose",
        "elicit",
        "evaluated",
        "evidence-based",
        "female",
        "follow-up",
        "frequency",
        "geriatric",
        "guidelines",
        "hematologic",
        "higher",
        "humans",
        "humoral",
        "igg-",
        "illness",
        "immune",
        "immunity",
        "immunization programs",
        "immunogenicity",
        "immunoglobulin",
        "immunoglobulin g",
        "implications",
        "important",
        "improved",
        "infections",
        "inform",
        "inhibitors",
        "level",
        "levels",
        "long-term",
        "longitudinal",
        "longitudinal studies",
        "lower",
        "male",
        "malignancies",
        "measured",
        "median",
        "middle aged",
        "modalities",
        "moderna sars-cov-2 vaccine",
        "months",
        "mrna",
        "mrna-1273",
        "needed",
        "neoplasms",
        "one",
        "optimize",
        "patient",
        "patients",
        "peak",
        "pfizer-biontech sars-cov-2 vaccine",
        "points",
        "populations",
        "prospective",
        "prospective studies",
        "received",
        "receiving",
        "reduced",
        "relative",
        "remained",
        "research",
        "respiratory",
        "response",
        "responses",
        "s-rbd",
        "sars-cov-2",
        "selection",
        "sequence",
        "severe",
        "shows",
        "significance",
        "solid",
        "studies",
        "study",
        "subjects",
        "surveys and questionnaires",
        "sustained",
        "syndrome",
        "tailor",
        "targeted",
        "therapeutic",
        "three",
        "time",
        "time factors",
        "timing",
        "trajectories",
        "treatment",
        "tumor",
        "tumors",
        "two",
        "type",
        "unvaccinated",
        "vaccinated",
        "vaccination",
        "vaccinations",
        "vaccine",
        "vaccine-induced",
        "vaccines",
        "variation",
        "various",
        "viral"
    ]
}